Free shipping on all orders over $ 500

CBL0137

Cat. No. M9302
CBL0137 Structure
Synonym:

Curaxin 137; CBLC137

Size Price Availability Quantity
5mg USD 360  USD360 In stock
10mg USD 640  USD640 In stock
25mg USD 990  USD990 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

CBL0137 is a metabolically stable curaxin that activates p53 with an EC50 value of 0.37 µM and inhibits NF-κB with an EC50 of 0.47 µM. CBL0137 inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. CBL0137 eradicates d rug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.

In mice, CBL0137 was effective against orthotopic gemcitabine resistant PANC-1 model and patient derived xenografts, in which CBL0137 anti-tumor effect related with overexpression of FACT. Moreover, the combination effects of CBL0137 and gemcitabine might be explained by the ability of CBL0137 to inhibit several transcriptional programs induced by gemcitabine, including NF-kappaB response and expression of ribonucleotide reductase.

Chemical Information
Molecular Weight 336.43
Formula C21H24N2O2
CAS Number 1197996-80-7
Solubility (25°C) DMSO 10 mM
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Lock R, et al. Pediatr Blood Cancer. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.

[2] Burkhart C, et al. Oncotarget. Curaxin CBL0137 eradicates d rug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.

Related p53 Products
BAY 1892005

BAY 1892005, a p53 protein modulator, is active on p53 condensates and does not lead to mutant p53 reactivation.

FOXO4-DRI

FOXO4-DRI is a cell-permeable peptide antagonist that blocks the interaction of FOXO4 and p53.

p53 (17-26)

p53 (17-26) is amino acids 17 to 26 fragment of p53.

Azurin p28 peptide

Azurin p28 peptide is a tumor-penetrated antitumor peptide.

INV-102

INV-102 is a p53 and Pax6 activator that can be used in studies related to dry eye.

  Catalog
Abmole Inhibitor Catalog




Keywords: CBL0137, Curaxin 137; CBLC137 supplier, p53, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.